📝 Shree Ganesh Remedies Ltd — results explained
Quarter ended June 2026 (Q1 FY27)
Shree Ganesh Remedies Ltd reported revenue of ₹14 crore for the quarter ended June 2026 (Q1 FY27), down 41.8% from ₹25 crore in the same quarter last year, and down 56.7% sequentially over the March 2026 quarter.
Net profit fell 67.5% year-on-year to ₹1 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹0.87.
Operating profit stood at ₹3 crore — an operating margin (OPM) of 23.3%, compared with 29.6% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Shree Ganesh Remedies Ltd posted revenue of ₹109 crore, a growth of 0.7% over FY25, with a net profit of ₹18 crore (down 23.0% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹99 crore with a net profit of ₹15 crore.
Valuation snapshot
At the current price of ₹657.55, 540737 has a market capitalisation of ₹855 crore and a trailing P/E of about 55.4.
Within the Pharmaceuticals industry, it is the 10th-largest of the 82 companies we track by market value.
Shareholding pattern
As of Mar 2026, promoters held 72.83%, foreign institutional investors (FIIs) 0.00%, public shareholders 27.16% of Shree Ganesh Remedies Ltd.